Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2004 1
2005 2
2006 5
2008 4
2010 2
2011 9
2012 16
2013 16
2014 7
2015 5
2016 13
2017 12
2018 16
2019 13
2020 14
2021 17
Text availability
Article attribute
Article type
Publication date

Search Results

136 results
Results by year
Filters applied: . Clear all
Page 1
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.
Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. Lee JC, et al. Among authors: yoshimoto k. PLoS Med. 2006 Dec;3(12):e485. doi: 10.1371/journal.pmed.0030485. PLoS Med. 2006. PMID: 17177598 Free PMC article.
[Visionary Approach to Neurosurgery].
Iihara K, Mizoguchi M, Yoshimoto K, Sayama T, Amano T, Hashiguchi K, Mori M, Nishimura A, Mukae N, Kawamura Y. Iihara K, et al. Among authors: yoshimoto k. Fukuoka Igaku Zasshi. 2015 Apr;106(4):65-70. Fukuoka Igaku Zasshi. 2015. PMID: 26117949 Free article. Review. Japanese. No abstract available.
[TSH-Secreting Pituitary Adenoma].
Fujio S, Yoshimoto K. Fujio S, et al. Among authors: yoshimoto k. No Shinkei Geka. 2018 Dec;46(12):1053-1063. doi: 10.11477/mf.1436203868. No Shinkei Geka. 2018. PMID: 30572302 Japanese. No abstract available.
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
Hata N, Mizoguchi M, Kuga D, Hatae R, Akagi Y, Sangatsuda Y, Amemiya T, Michiwaki Y, Fujioka Y, Takigawa K, Suzuki SO, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iihara K. Hata N, et al. Among authors: yoshimoto k. J Neurooncol. 2020 Feb;146(3):451-458. doi: 10.1007/s11060-019-03339-0. Epub 2020 Feb 4. J Neurooncol. 2020. PMID: 32020475
Loss of heterozygosity analysis in malignant gliomas.
Mizoguchi M, Kuga D, Guan Y, Hata N, Nakamizo A, Yoshimoto K, Sasaki T. Mizoguchi M, et al. Among authors: yoshimoto k. Brain Tumor Pathol. 2011 Jul;28(3):191-6. doi: 10.1007/s10014-011-0038-0. Epub 2011 Jun 1. Brain Tumor Pathol. 2011. PMID: 21629980 Review.
A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N, Akahane T, Yokoyama S, Yonezawa H, Uchida H, Takajo T, Kirishima M, Hamada T, Matsuo K, Fujio S, Hanada T, Hosoyama H, Yonenaga M, Sakamoto A, Hiraki T, Tanimoto A, Yoshimoto K. Higa N, et al. Among authors: yoshimoto k. Cancer Sci. 2020 Oct;111(10):3902-3911. doi: 10.1111/cas.14597. Epub 2020 Sep 6. Cancer Sci. 2020. PMID: 32748499 Free PMC article.
136 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page